Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation.

× No keyword cloud information.

22 in total

Review 1. Permanent neonatal diabetes due to activating mutations in ABCC8 and KCNJ11.

Authors: Emma L Edghill; Sarah E Flanagan; Sian Ellard
Journal: Rev Endocr Metab Disord Date: 2010-09 Impact factor: 6.514

2. Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene.

Authors: G Tonini; C Bizzarri; R Bonfanti; M Vanelli; F Cerutti; E Faleschini; F Meschi; F Prisco; E Ciacco; M Cappa; C Torelli; V Cauvin; S Tumini; D Iafusco; F Barbetti
Journal: Diabetologia Date: 2006-07-01 Impact factor: 10.122

Review 3. Neonatal diabetes mellitus: a model for personalized medicine.

Authors: Siri Atma W Greeley; Susan E Tucker; Rochelle N Naylor; Graeme I Bell; Louis H Philipson
Journal: Trends Endocrinol Metab Date: 2010-04-29 Impact factor: 12.015

4. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.

Authors: A S Slingerland; R Nuboer; M Hadders-Algra; A T Hattersley; G J Bruining
Journal: Diabetologia Date: 2006-09-19 Impact factor: 10.122

5. Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons.

Authors: David Carmody; Charles D Bell; Jessica L Hwang; Jazzmyne T Dickens; Daniela I Sima; Dania L Felipe; Carrie A Zimmer; Ajuah O Davis; Kateryna Kotlyarevska; Rochelle N Naylor; Louis H Philipson; Siri Atma W Greeley
Journal: J Clin Endocrinol Metab Date: 2014-12 Impact factor: 5.958

6. Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype.

Authors: S E Flanagan; E L Edghill; A L Gloyn; S Ellard; A T Hattersley
Journal: Diabetologia Date: 2006-04-12 Impact factor: 10.122

7. Evaluation of the pharmacokinetics of glibenclamide tablet given, off label, orally to children suffering from neonatal syndromic hyperglycemia.

Authors: Naïm Bouazza; Zoubir Djerada; Claire Gozalo; Kanetee Busiah; Jacques Beltrand; Marianne Berdugo; Saik Urien; Jean-Marc Treluyer; Michel Polak
Journal: Eur J Clin Pharmacol Date: 2016-08-25 Impact factor: 2.953

Review 8. Infantile onset diabetes mellitus in developing countries - India.

Authors: Poovazhagi Varadarajan
Journal: World J Diabetes Date: 2016-03-25

9. Sulfonylurea therapy in two Korean patients with insulin-treated neonatal diabetes due to heterozygous mutations of the KCNJ11 gene encoding Kir6.2.

Authors: Min Sun Kim; Sun Young Kim; Gu Hwan Kim; Han Wook Yoo; Dong Whan Lee; Dae Yeol Lee
Journal: J Korean Med Sci Date: 2007-08 Impact factor: 2.153

10. Tooth discoloration in patients with neonatal diabetes after transfer onto glibenclamide: a previously unreported side effect.

Authors: Janani Kumaraguru; Sarah E Flanagan; Siri Atma W Greeley; Roos Nuboer; Julie Støy; Louis H Philipson; Andrew T Hattersley; Oscar Rubio-Cabezas
Journal: Diabetes Care Date: 2009-05-12 Impact factor: 19.112